• P62 The Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Melanoma – Findings from a UK Melanoma Registry

    Jan 1, 2022, 00:00

  • POSA254 An Initial Framework to Describe and Classify Integrated Scientific Advice Procedures for Vaccines

    Jan 1, 2022, 00:00

  • POSB89 Healthcare Resource Use and Costs of Treating Patients with MDD and Suicidal Ideation or Behaviour in Europe

    Jan 1, 2022, 00:00

  • POSA60 Clinical and Economic Burden of Spinal Muscular Atrophy in France

    Jan 1, 2022, 00:00

  • POSB327 Assessing the Benefits of Improving Health-Related Quality of Life in Heart Failure: A Preliminary Analysis in EU, UK, and Canada

    Jan 1, 2022, 00:00

  • POSC30 Associations Between Physical Function Measures and Patient Reported Outcomes in Pompe Disease and Other Rare Disorders Impacting Motor, Respiratory, and Skeletal Function

    Jan 1, 2022, 00:00

  • POSC236 Atopic Dermatitis: Trends in Real-World Treatment Patterns in Dermatology Specialty Networks

    Jan 1, 2022, 00:00

  • POSA40 Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) Versus Tiotropium Monotherapy in Patients with COPD in the UK

    Jan 1, 2022, 00:00

  • POSC314 Indirect Treatment Comparison: A Proposed Decision Algorithm to Define the Best Approach

    Jan 1, 2022, 00:00

  • POSA11 Ceftolozane-Tazobactam for the Treatment of Complicated Infections in Hospital Settings - Results from a French Real-World Study

    Jan 1, 2022, 00:00

  • POSB162 Cost-Effectiveness Analysis of Intravascular Ultrasound in Percutaneous Coronary Intervention

    Jan 1, 2022, 00:00

  • POSA278 A Comprehensive Overview of New HTA Guideline for Medicines in Ukraine

    Jan 1, 2022, 00:00

  • P66 Epidemiology of Non-Small Cell Lung Cancer (NSCLC) by Histology and Disease Stage in Western Europe (WE): Population-Level Projections 2021-2026

    Jan 1, 2022, 00:00

  • POSB92 Potential Budget Impact of Negative Pressure Wound Therapy with Instillation and Dwell Versus Control Therapy Across Multiple Geographies

    Jan 1, 2022, 00:00

  • POSC289 Cost-Effectiveness of Vagus Nerve Stimulation with Anti-Seizure Medication Versus Anti-Seizure Medication Alone in the Management of Drug Resistant Epilepsy in England

    Jan 1, 2022, 00:00

  • POSA143 Budget Impact Analysis for the Use of Dupilumab in Patients with Severe Asthma in Colombia

    Jan 1, 2022, 00:00

  • Methodological Developments in Network Meta-Analysis and Comparative Effectiveness Research

    Jan 1, 2022, 00:00

  • POSB100 Cost-Comparison Model of Brolucizumab for the Treatment of Age-Related Macular Degeneration

    Jan 1, 2022, 00:00

  • POSC156 Clinical Burden, Treatment Pathway, and Healthcare Resource Utilization of Transfusion-Dependent Beta-Thalassemia Patients in Italy: A Retrospective Analysis

    Jan 1, 2022, 00:00

  • POSB81 Annual Health Insurance Treatment Cost of Heart Failure, Unspecified Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSC349 Is Delayed Recall Affected By Anxiety in a Memory-Impaired Clinic Population?

    Jan 1, 2022, 00:00

  • P26 The Practice of Face Masking Among Young Adults in South India: An Online Cross-Sectional Survey During Second Wave of COVID-19

    Jan 1, 2022, 00:00

  • POSC283 Number Needed to Treat and Incremental Costs per Responder for Biologics and Targeted Synthetic Drugs in Adult Patients with Active Psoriatic Arthritis in the Russian Federation

    Jan 1, 2022, 00:00

  • POSA255 A Multi-Criteria Decision Analysis in Health Technology Assessment for All Drugs in Russia

    Jan 1, 2022, 00:00

  • POSB41 Real-World Assessment of Healthcare Resource Utilisation and Direct Medical Costs in Patients with COPD Receiving ICS/LABA Therapy in England

    Jan 1, 2022, 00:00

  • POSB106 Economic Burden of Metastatic Colorectal Cancer Patients in Greece

    Jan 1, 2022, 00:00

  • POSA345 Characterising Patient Preferences for Treatment Attributes in Heart Failure with Preserved Ejection Fraction

    Jan 1, 2022, 00:00

  • POSB302 Assessing the Viability of a Surrogacy Relationship between Disease-Free Survival (DFS) and Overall Survival (OS) for the Patients in Clinical Trials for Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) Following Ra ...

    Jan 1, 2022, 00:00

  • P24 Telehealth Access and Use by the U.S. Medicare Population during the Pandemic

    Jan 1, 2022, 00:00

  • POSC287 Improving Outcomes Research in Digital Health - Results of a Systematic Scoping Literature Review

    Jan 1, 2022, 00:00

  • POSA344 Willingness-to-Pay and Preferences of Patients Undergoing a Cystoscopy: Results from a Large Survey-Based Study in Spain

    Jan 1, 2022, 00:00

  • POSC70 The Economic and Social Burden of Spinal Muscular Atrophy (SMA) in the Italian Context

    Jan 1, 2022, 00:00

  • POSC254 The Impact of COVID-19 on European HTA Decisions

    Jan 1, 2022, 00:00

  • POSC176 Is Pain Severity Associated with Functional Limitations Among United States Adults? A Cross-Sectional Study Using 2018 Medical Expenditure Panel Survey

    Jan 1, 2022, 00:00

  • POSA363 Lasting Impacts of the COVID-19 Pandemic on Patients Affected By Chronic Diseases in Europe

    Jan 1, 2022, 00:00

  • POSA322 Applying Machine Learning to Identify Predictors of Major Bleeding Among Patients with Atrial Fibrillation Who Initialized Oral Anticoagulants in the Clinical Practice Research Datalink and Hospital Episode Statistics

    Jan 1, 2022, 00:00

  • P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective

    Jan 1, 2022, 00:00

  • POSB360 Perception of COVID-19 Vaccination Among Chronic Patients: To Be or Not to Be Vaccinated?

    Jan 1, 2022, 00:00

  • POSA334 Changes in the Quality of Life of Patients with Major Arthroplasty

    Jan 1, 2022, 00:00

  • POSC225 Challenges Regarding Implementation of Performance-Based Managed Entry Agreements (MEAS) for Advanced Therapy Medicinal Products (ATMPS)

    Jan 1, 2022, 00:00

  • POSA90 Annual Health Insurance Treatment Cost of Left Ventricular Failure Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSA156 Real-World Analysis of the Healthcare Resource Consumption and Related Costs of Sickle Cell Disease in Italy

    Jan 1, 2022, 00:00

  • Emerging Opportunities for the Use of Real World Data in Comparative Effectiveness Research

    Jan 1, 2022, 00:00

  • POSB94 Impact of Choice of Inhalers for Asthma Care on Global Carbon Footprint and Societal Costs: A Long-Term Economic Evaluation

    Jan 1, 2022, 00:00

  • POSC134 Cost-Effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer

    Jan 1, 2022, 00:00

  • POSC370 Health-Related Quality of Life of Naratuximab Emtasine + Rituximab (N+R) in Second Line and Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): An Analysis of the Functional Assessment ...

    Jan 1, 2022, 00:00

  • POSA178 The Impact of Non-Melanoma Skin Cancer in Portugal

    Jan 1, 2022, 00:00

  • POSB85 Deprescribing Interventions for Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations

    Jan 1, 2022, 00:00

  • POSA248 Consistency of Metastatic Non-Small Cell Lung Cancer and Renal Cell Carcinoma Treatment Patterns Across Italian Regions

    Jan 1, 2022, 00:00

  • POSB337 Comparison Between Thoracic Spine Deformities and Impingement Syndrome Among Volleyball Players in Different Age Groups

    Jan 1, 2022, 00:00

  • POSC150 Cost-Effectiveness of Implantable Cardioverter Defibrillators (ICD) for Sudden Death Prevention after Myocardial Infarction in Russian Federation

    Jan 1, 2022, 00:00

  • POSC136 Budget Impact Analysis of Implementing an Autotransfusion System in Cardiovascular Surgery at a Hospital Level in Saudi Arabia

    Jan 1, 2022, 00:00

  • POSA200 Characterization of Atopic Dermatitis Patients Treated in Colombia

    Jan 1, 2022, 00:00

  • POSC416 The Cost of Haemophilia in Men - A Socioeconomic Survey (CHESS) II Study: Methods: and Key Results

    Jan 1, 2022, 00:00

  • POSC387 A Real-World Study of Biologic-Eligible Atopic Dermatitis Patients in Taiwan

    Jan 1, 2022, 00:00

  • POSA336 The Importance of Footballers Core Muscle Stability in Terms of Injuries, Especially the Hamstring Muscles

    Jan 1, 2022, 00:00

  • POSC21 Biologicals in the Treatment of Severe Asthma: Effectiveness, Safety and Economic Impact Using Hospital Real-World Data

    Jan 1, 2022, 00:00

  • POSB211 Is an Early Access Program for an Oncology Drug an Asset in the French Pricing and Reimbursement Pathway?

    Jan 1, 2022, 00:00

  • POSA285 Review of NICE Submissions in Multiple Sclerosis to Assess Differences between Label Populations and NICE Recommendations

    Jan 1, 2022, 00:00

  • POSB339 Real-World Adherence of Nusinersen for the Treatment of Spinal Muscular Atrophy (SMA) Using US Large Administrative Claims Dataset

    Jan 1, 2022, 00:00

  • POSA137 Cost-Effectiveness Analysis of a New Anticalcification Treatment Tissue Valve vs. Mechanical Heart Valves in Subgroups of People Aged 55-64 and >65 with Aortic Stenosis (AS) Suitable for Surgical Aortic Valve Replacement (SAVR)

    Jan 1, 2022, 00:00

  • POSB280 Review of Real-World Data Use in French Economic and Public Health Assessment Committee's (CEESP) Efficiency Opinions for Anticancer Drugs

    Jan 1, 2022, 00:00

  • POSA263 How Do the Pricing and Reimbursement Policies for Digital Therapeutics Compare and Contrast Between the US, EU-5, China and Japan?

    Jan 1, 2022, 00:00

  • POSC234 Impact of Community Pharmacies on Access to Point-of-Care Tests for HIV and Hepatitis C and B Infections: An Observational, Cross-Sectional Study

    Jan 1, 2022, 00:00

  • POSB345 Updated 2018 - 2020 Review of Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration

    Jan 1, 2022, 00:00

  • POSB219 A Framework for Gene Therapy Disease Area Targeting

    Jan 1, 2022, 00:00

  • POSC102 High-Flow Nasal Cannula in Patients with COVID-19: Is a Cost-Effective Alternative?

    Jan 1, 2022, 00:00

  • POSC273 Has IQWiG's 15% Response Threshold Made a Minimally Important Difference to Benefit Assessments?

    Jan 1, 2022, 00:00

  • POSB357 Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

    Jan 1, 2022, 00:00

  • Decision Modeling and Simulation

    Jan 1, 2022, 00:00

  • POSA318 Automation of Title and Abstract Screening: CAN Robots Replace Humans?

    Jan 1, 2022, 00:00

  • P32 Price Analysis of Cancer Therapies for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

    Jan 1, 2022, 00:00

  • POSA103 Estimation of the Economic and Social Burden of Pulmonary Arterial Hypertension in Spain

    Jan 1, 2022, 00:00

  • POSA165 Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review

    Jan 1, 2022, 00:00

  • POSA131 Costs of Relapsed/Refractory Acute Myeloid Leukemia (AML) in Colombia

    Jan 1, 2022, 00:00

  • POSB54 Breast Cancer: The Economic Burden of Social Security Benefits in Italy

    Jan 1, 2022, 00:00

  • POSA355 Pan-European Study on the Management of Medication Adheren A Study Protocol By Cost Action 'Enable' Working Group 1

    Jan 1, 2022, 00:00

  • P50 Competing Risk and Multistate Model Compared to Partitioned Survival Model in Metastatic Non-Small Cell Lung Cancer

    Jan 1, 2022, 00:00

  • POSA27 Are Digital Endpoints Being Used To Support Labelling Claims? A Status Check

    Jan 1, 2022, 00:00

  • POSC199 A Retrospective Database Analysis of Erythropoiesis-Stimulating Agent Treatment Patterns and Associated Healthcare Resource Use in Non–Dialysis-Dependent Chronic Kidney Disease Patients with Anaemia in Japan

    Jan 1, 2022, 00:00

  • POSB177 Epidemiological Disease Burden of Other Cataract Based on Routinely Collected Health Insurance Claims DATA

    Jan 1, 2022, 00:00

  • POSB419 Total Knee Arthroplasty: Do Outcomes Differ By Implant Design in the Real World?

    Jan 1, 2022, 00:00

  • POSC173 The Association Between Physical Activity, Body Mass Index and Health Complaints Among Hungarian School-Aged Children

    Jan 1, 2022, 00:00

  • POSB166 Exploring the Impact of Heterogeneity in Economic Evaluations: Current Practice and Implications

    Jan 1, 2022, 00:00

  • POSB120 Economic Assessment of Ribociclib for the Treatment of Postmenopausal Patients with Advanced Breast Cancer HR-Positive, HER2-Negative.

    Jan 1, 2022, 00:00

  • POSB298 DRG-Based Reimbursement and Payment Modalities for Innovative Remote Patient Monitoring Technologies

    Jan 1, 2022, 00:00

  • Access to Care/Real World Evidence to Inform Decision Making

    Jan 1, 2022, 00:00

  • POSA209 The Role of Economic Evaluation in the P R in Italy

    Jan 1, 2022, 00:00

  • POSC195 What Is the Burden of Varicella-Associated Complications: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC209 Cost of Treatment with Biosimilars - Case with Rituximab in Oncohematology

    Jan 1, 2022, 00:00

  • POSC238 Real World Data of Acute Pain Prescription in a Health District

    Jan 1, 2022, 00:00

  • POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada

    Jan 1, 2022, 00:00

  • POSC46 A Cost-Effectiveness Analysis of Patiromer for the Treatment of Hyperkalemia in Spain

    Jan 1, 2022, 00:00

  • POSB30 Systematic Literature Review of Clinical, Economic, and Patient-Reported Benefits of Connected Insulin Pen Systems

    Jan 1, 2022, 00:00

  • POSA342 Reported Utilities and Health-Related Quality of Life (HRQOL) Data for Patients with Muscle Invasive Urothelial Carcinoma (MIUC) Treated with Radical Resection (RR): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSB99 The Cost-Effectiveness of Biologic/Targeted Synthetic/Biosimilar Disease Modifying Antirheumatic Drugs: A Systematic Review

    Jan 1, 2022, 00:00

  • POSB228 Clinical Effectiveness of Facility Based Interventions to Improve Uptake of Dual Contraception Among Women Living with HIV: A Systematic Review and Meta Analysis

    Jan 1, 2022, 00:00

  • POSB382 Perceptions about Biosimilar Medicines Among Belgian Ambulatory Care Patients

    Jan 1, 2022, 00:00

  • POSB135 Budget Impact Analysis of Brigatinib for First-line Treatment of Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Italy

    Jan 1, 2022, 00:00

  • POSA192 Disease Burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: Signs and Symptoms

    Jan 1, 2022, 00:00

  • POSC69 Healthcare Resource Consumption Associated with Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D) in Italy

    Jan 1, 2022, 00:00

  • POSB340 Availability of Published Health-Related Quality of Life (HRQOL) Data for Patients Receiving First-Line (1L) Treatment for Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSB193 COVID-19 Vaccine Development Pipeline: 2021

    Jan 1, 2022, 00:00

  • POSB351 A Prospective Observational Study to Determine the Safety, Efficacy, and Toxicity Profile of Paclitaxel in Patients Receiving Weekly and Three Weekly Doses

    Jan 1, 2022, 00:00

  • POSA121 Modelling Long-Term Outcomes and Mortality Risk for Post-Stroke Spasticity Patients on Abobotulinumtoxina Treatment and Rehabilitation Therapy

    Jan 1, 2022, 00:00

  • POSC141 Evaluation of the Long-Term Cost-Effectiveness of Ideglira Versus Liraglutide for Patients with Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs in China

    Jan 1, 2022, 00:00

  • POSA428 The Impact of Treatment Effect Parameterization in Mixture Cure Models on Survival Estimates and Uncertainty

    Jan 1, 2022, 00:00

  • POSB369 Development of the Patient-Reported Impact of Dermatological Diseases (PRIDD) Measure

    Jan 1, 2022, 00:00

  • POSA195 Assessment of Consumption of Antidepressant Drugs in Ukraine in 2015-2019

    Jan 1, 2022, 00:00

  • POSA213 Product Development Partnerships (PDPS) and Pharmaceutical Innovation

    Jan 1, 2022, 00:00

  • POSB322 The Goal Attainment Scaling Method Is Robust to Violations of Normality in Goal Scales: A Simulation Study

    Jan 1, 2022, 00:00

  • P34 Use of Social Media Listening (SML) Methods for Understanding the Patient Experience of Chronic Disease: A Scoping Review

    Jan 1, 2022, 00:00

  • POSA312 Exploring Health Related Factors Indicating Susceptibility to COVID19

    Jan 1, 2022, 00:00

  • POSA306 Recommended Approaches for Analyzing Clinical Outcomes Assessment Data from Oncology Trials for Different Stakeholders

    Jan 1, 2022, 00:00

  • POSB347 Patients' Quality of Life and Clinical Outcomes of Emicizumab Prophylaxis Therapy for the Severe Haemophilia a Treatment in China

    Jan 1, 2022, 00:00

  • POSB305 Assessing the Reliability and Validity of an Instrument Used to Measure Student Pharmacists' Experiences of Teamwork in a Quality Improvement Course

    Jan 1, 2022, 00:00

  • POSA113 The Cost Analysis of the Environmental Impacts of Surgical Site Infection from the Perspective of NHS England

    Jan 1, 2022, 00:00

  • POSA188 Epidemiological Disease Burden of Non-Insulin-Dependent Diabetes with Peripheral Circulatory Complications Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSB140 Healthcare Utilization and Costs of Human Papillomavirus (HPV) Associated Anogenital Diseases in Young Women: An Analysis of Statutory Health Insurance Claims Data from Germany

    Jan 1, 2022, 00:00

  • POSA168 Meta-Analysis and Cost-Effectiveness Analysis of Oxaliplatin-Based Chemotherapy Versus Irinotecan-Based Chemotherapy for the First-Line Treatment of Metastatic Advanced Colorectal Cancer in China

    Jan 1, 2022, 00:00

  • POSC365 Health State Utilities of Advanced Melanoma Patients Treated in Clinical Practice in the Era of Novel Immuno- and Targeted Therapies

    Jan 1, 2022, 00:00

  • POSB249 Retrospective Analysis of Real-World Clinical Outcomes and Healthcare Resource Consumption in Patients with Chronic Kidney Disease With and Without Secondary Hyperparathyroidism in Italy

    Jan 1, 2022, 00:00

  • POSB423 Incident Versus Prevalent Population: Review of Guidelines to Estimate the Eligible Population for Budget Impact Analysis

    Jan 1, 2022, 00:00

  • POSB378 Health State Utilities Associated with Hyperphagia

    Jan 1, 2022, 00:00

  • POSA304 Cost-Effectiveness Modelling Structures for Chronic Rhinosinusitis with Nasal Polyps - A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC146 Cost-Effectiveness of Adherence in Newly Treated Tuberculosis Patients Using Discrete Event Simulation

    Jan 1, 2022, 00:00

  • POSA294 Meta-Analysis of Effectiveness of Self-Monitoring of Blood Glucose in Type 2 Diabetes

    Jan 1, 2022, 00:00

  • POSC166 Cost-Effectiveness of Emicizumab Prophylaxis Therapy Versus Recombinant Activated FVII On-Demand Therapy for Hemophilia A with Inhibitors in China

    Jan 1, 2022, 00:00

  • POSB82 Annual Health Insurance Treatment Cost of Malignant Neoplasm of Other and Ill-Defined Sites in the LIP, Oral Cavity, and Pharynx Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSA162 Modeling the Ex Ante Real Option Value in a Highly Innovative Therapeutic Area: ALK-Positive Non-Small Cell Lung Cancer

    Jan 1, 2022, 00:00

  • POSC151 Cost-Effectiveness Analysis of Ribociclib in Ecuadorian Women with Advanced Breast Cancer

    Jan 1, 2022, 00:00

  • POSA244 First-Line Maintenance (1L MT) Treatment of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Western Europe (WE): Results of the CancerMPact® Survey 2020

    Jan 1, 2022, 00:00

  • POSC60 Assessing the Pattern of Healthcare Costs Among Older United States Adults with Varying Pain Severities

    Jan 1, 2022, 00:00

  • POSC421 Understanding the Impact of Congress Abstracts on Overall Publications in Multiple Myeloma (MM) - Results of a Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • Table of Contents

    Dec 1, 2021, 00:00

  • Patient Preferences for Anxiety and Depression Screening in Cancer Care: A Discrete Choice Experiment

    Dec 1, 2021, 00:00

  • Retrospectively Collected EQ-5D-5L Data as Valid Proxies for Imputing Missing Information in Longitudinal Studies

    Dec 1, 2021, 00:00

  • Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data

    Dec 1, 2021, 00:00

  • Supporting Informal Caregivers of People With Dementia in Cost-Effective Ways: A Systematic Review and Meta-Analysis

    Dec 1, 2021, 00:00

  • Adherence to Clinical Practice Guideline Recommendations on Low-Value Injury Care: A Multicenter Retrospective Cohort Study

    Dec 1, 2021, 00:00

  • Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019 [Editor's Choice]

    Dec 1, 2021, 00:00

  • Valuation of Informal Care Provided to People Living With Dementia: A Systematic Literature Review

    Dec 1, 2021, 00:00

  • Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs

    Dec 1, 2021, 00:00

  • A Review of Current Approaches to Defining and Valuing Innovation in Health Technology Assessment [Editor's Choice]

    Dec 1, 2021, 00:00

  • Cost-Effective Analysis of Dual-Energy Computed Tomography for the Diagnosis of Occult Hip Fractures Among Older Adults

    Dec 1, 2021, 00:00

  • Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma

    Dec 1, 2021, 00:00

  • Inclusion of Patient-Reported Outcomes in Adolescent and Young Adult Phase III Therapeutic Trials: An Analysis of Cancer Clinical Trials Registered on ClinicalTrials.gov [Editor's Choice]

    Dec 1, 2021, 00:00

  • Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer

    Dec 1, 2021, 00:00

  • Comparison of the Psychometric Properties of the EQ-5D-3L-Y and EQ-5D-5L-Y Instruments in Spanish Children and Adolescents

    Dec 1, 2021, 00:00

  • Copyright/Subscription

    Dec 1, 2021, 00:00

  • Coverage and Pricing Recommendations of the French National Health Authority for Innovative Drugs: A Retrospective Analysis From 2014 to 2020

    Dec 1, 2021, 00:00

  • Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study

    Dec 1, 2021, 00:00

  • Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? [Editor's Choice]

    Dec 1, 2021, 00:00

  • Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment

    Dec 1, 2021, 00:00

  • Editorial Board

    Nov 29, 2021, 08:32

  • Patient Self-Reported Health, Clinical Quality, and Patient Satisfaction in English Primary Care: Practice-Level Longitudinal Observational Study

    Nov 1, 2021, 00:00

  • Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence?

    Nov 1, 2021, 00:00

  • Predicting Hospital Resource Use During COVID-19 Surges: A Simple but Flexible Discretely Integrated Condition Event Simulation of Individual Patient-Hospital Trajectories

    Nov 1, 2021, 00:00

  • Table of Contents

    Nov 1, 2021, 00:00

  • Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis

    Nov 1, 2021, 00:00

  • Cost-Effectiveness of Magnetic Resonance Imaging-Guided Thrombolysis for Patients With Stroke With Unknown Time of Onset

    Nov 1, 2021, 00:00

  • Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses

    Nov 1, 2021, 00:00

  • Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis

    Nov 1, 2021, 00:00

  • The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study [Editor's Choice]

    Nov 1, 2021, 00:00

  • Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations [Editor's Choice]

    Nov 1, 2021, 00:00

  • Costing of Essential Health Service Packages: A Systematic Review of Methods From Developing Economies

    Nov 1, 2021, 00:00

  • Evidence of Stability in Patient-Reported Global Health During the COVID-19 Pandemic

    Nov 1, 2021, 00:00

  • Copyright/Subscription

    Nov 1, 2021, 00:00

  • Will Americans Get Vaccinated? Predicting COVID-19 Vaccine Uptake Rates Under Contingent Scenarios [Editor's Choice]

    Nov 1, 2021, 00:00

  • Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective

    Nov 1, 2021, 00:00

  • Cost-Effectiveness of COVID-19 Policy Measures: A Systematic Review [Editor's Choice]

    Nov 1, 2021, 00:00

  • A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions

    Nov 1, 2021, 00:00

  • Impact of Persisting Amblyopia on Socioeconomic, Health, and Well-Being Outcomes in Adult Life: Findings From the UK Biobank

    Nov 1, 2021, 00:00

  • Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study

    Nov 1, 2021, 00:00

  • Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys

    Nov 1, 2021, 00:00

  • Editorial Board

    Oct 26, 2021, 08:19

  • Government, Big Pharma, and the People: A Century of Dis-Ease. By Smith MC, Kolassa EM, Pray WS. Routledge. Taylor & Francis Group; 2021.

    Oct 5, 2021, 16:04

  • Editorial Board

    Oct 4, 2021, 17:53

  • Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy

    Oct 1, 2021, 00:00

  • Toward Better Data Dashboards for US Drug Value Assessments [Editor's Choice]

    Oct 1, 2021, 00:00

  • A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain

    Oct 1, 2021, 00:00

  • How Much Is a Human Life Worth? A Systematic Review [Editor's Choice]

    Oct 1, 2021, 00:00

  • Quantifying Value of Hope [Editor's Choice]

    Oct 1, 2021, 00:00

  • Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL

    Oct 1, 2021, 00:00

  • Development and Psychometric Testing of the Caregiver Self-Efficacy in Contributing to Patient Self-Care Scale

    Oct 1, 2021, 00:00

  • Copyright/Subscription

    Oct 1, 2021, 00:00

  • Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations

    Oct 1, 2021, 00:00

  • Cost-Effectiveness Analysis of Branded Drugs With Market Demand and Insurance [Editor's Choice]

    Oct 1, 2021, 00:00

  • Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma

    Oct 1, 2021, 00:00

  • How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations [Editor's Choice]

    Oct 1, 2021, 00:00

  • Social Impact of Prophylactic Migraine Treatments in Germany: A State-Transition and Open Cohort Approach

    Oct 1, 2021, 00:00

  • Table of Contents

    Oct 1, 2021, 00:00

  • Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective

    Oct 1, 2021, 00:00

  • Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure

    Oct 1, 2021, 00:00

  • Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients With Duchenne Muscular Dystrophy

    Oct 1, 2021, 00:00

  • Encouraging Mammograms Using Behavioral Economics: A Randomized Controlled Trial in Chile

    Oct 1, 2021, 00:00

  • Estimation of the Width of Uncertainty in Care Consumption and Costs When Using Common Data Collection Tools in Economic Evaluations: A Benchmark for Sensitivity Analyses

    Oct 1, 2021, 00:00

  • Mapping EQ-5D-3L to EQ-5D-5L [Editor's Choice]

    Sep 1, 2021, 00:00

  • Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based? [Editor's Choice]

    Sep 1, 2021, 00:00

  • Reference Values and Psychometric Properties of the Quality of Life After Traumatic Brain Injury-Overall Scale in Italy, The Netherlands, and the United Kingdom

    Sep 1, 2021, 00:00

  • Comparison of Parametric Survival Extrapolation Approaches Incorporating General Population Mortality for Adequate Health Technology Assessment of New Oncology Drugs [Editor's Choice]

    Sep 1, 2021, 00:00

  • To What Extent Do Patient Preferences Differ From General Population Preferences? [Editor's Choice]

    Sep 1, 2021, 00:00

  • Branded Price Variation in the United States Drug Market, 2010 to 2019

    Sep 1, 2021, 00:00

  • Cost-Effectiveness of Pulmonary Rehabilitation in Patients With Bronchial Asthma: An Analysis of the EPRA Randomized Controlled Trial

    Sep 1, 2021, 00:00

  • Measuring Financial Burden in Families of Children Living With Life-Limiting Conditions: A Scoping Review of Cost Indicators and Outcome Measures

    Sep 1, 2021, 00:00

  • Opioid Prescribing in United States Health Systems, 2015 to 2019

    Sep 1, 2021, 00:00

  • Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact

    Sep 1, 2021, 00:00

  • New Zealand Population Norms for the EQ-5D-5L Constructed From the Personal Value Sets of Participants in a National Survey

    Sep 1, 2021, 00:00

  • Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States

    Sep 1, 2021, 00:00

  • Cost-Effectiveness of Food Allergy Interventions in Children: A Systematic Review of Economic Evaluations

    Sep 1, 2021, 00:00

  • Table of Contents

    Sep 1, 2021, 00:00

  • Programmatic Costs of the Telehealth Ostomy Self-Management Training: An Application of Time-Driven Activity-Based Costing

    Sep 1, 2021, 00:00

  • Copyright/Subscription

    Sep 1, 2021, 00:00

  • Influence of Shared Decision Making on Decisional Conflict and Regret in Postpartum Mother–Infant Care: A Randomized Controlled Trial

    Sep 1, 2021, 00:00

  • Drug Prices and Value of Oncology Drugs in Italy

    Sep 1, 2021, 00:00

  • Long-Term Cost-Effectiveness of Smoking Cessation Interventions in People With Mental Disorders: A Dynamic Decision Analytical Model

    Sep 1, 2021, 00:00

  • Patient-Reported Outcomes After Treatment Discontinuation: Commercial Clinical Trial Data From Four Cancer Types

    Sep 1, 2021, 00:00

  • Editorial Board

    Aug 25, 2021, 09:42

  • Copyright/Subscription

    Aug 9, 2021, 09:02

  • Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients

    Aug 1, 2021, 00:00

  • Mitigating Nonattendance Using Clinic-Resourced Incentives Can Be Mutually Beneficial: A Contingency Management-Inspired Partially Observable Markov Decision Process Model

    Aug 1, 2021, 00:00

  • Mapping World Health Organization Quality of Life–BREF Onto 5-Level EQ-5D in Thai Patients With Chronic Diseases

    Aug 1, 2021, 00:00

  • Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation

    Aug 1, 2021, 00:00

  • Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review

    Aug 1, 2021, 00:00

  • How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments

    Aug 1, 2021, 00:00

  • Editorial Board

    Aug 1, 2021, 00:00

  • Author Reply

    Aug 1, 2021, 00:00

  • Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States

    Aug 1, 2021, 00:00

  • Systematic Review on Pain-Related Outcome Domains After Sternotomy: A First Step Toward the Development of a Core Outcome Set

    Aug 1, 2021, 00:00

  • Table of Contents

    Aug 1, 2021, 00:00

  • Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression Analysis [Editor's Choice]

    Aug 1, 2021, 00:00

  • Costs and Cost-Effectiveness of Malaria Control Interventions: A Systematic Literature Review

    Aug 1, 2021, 00:00

  • Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings

    Aug 1, 2021, 00:00

  • Development and Validation of an Instrument to Measure Health-Related Out-of-Pocket Costs: The Cost for Patients Questionnaire [Editor's Choice]

    Aug 1, 2021, 00:00

  • The CAPACITI Decision-Support Tool for National Immunization Programs [Editor's Choice]

    Aug 1, 2021, 00:00

  • Indirect Economic Burden of Sickle Cell Disease [Editor's Choice]

    Aug 1, 2021, 00:00

  • Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials [Editor's Choice]

    Aug 1, 2021, 00:00

  • Bias Assessment in Outcomes Research: The Role of Relative Versus Absolute Approaches

    Aug 1, 2021, 00:00

  • Inadequate Selection and Treatment Results in Poor Outcomes and Lack of Cost-Effectiveness

    Aug 1, 2021, 00:00

  • Editorial Board

    Jul 6, 2021, 08:41

  • Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland

    Jul 1, 2021, 00:00

  • Cost-Effectiveness of Propofol (Diprivan) Versus Inhalational Anesthetics to Maintain General Anesthesia in Noncardiac Surgery in the United States

    Jul 1, 2021, 00:00

  • Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases

    Jul 1, 2021, 00:00

  • Catalog of Age- and Medical Condition—Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis [Editor's Choice]

    Jul 1, 2021, 00:00

  • Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study

    Jul 1, 2021, 00:00

  • Think of the Children: A Discussion of the Rationale for and Implications of the Perspective Used for EQ-5D-Y Health State Valuation

    Jul 1, 2021, 00:00

  • Evaluating Complex Health and Social Care Program Using Multi-Criteria Decision Analysis: A Case Study of “Better Together in Amsterdam North”

    Jul 1, 2021, 00:00

  • Considerations for Cost-Effectiveness Analysis in Oncology

    Jul 1, 2021, 00:00

  • Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration–Approved Labeling, 2009 to 2019

    Jul 1, 2021, 00:00

  • Author’s Reply

    Jul 1, 2021, 00:00

  • Accounting for Heterogeneity in Resource Allocation Decisions: Methods and Practice in UK Cancer Technology Appraisals

    Jul 1, 2021, 00:00

  • Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review

    Jul 1, 2021, 00:00

  • Measuring Attitudes About Genomic Medicine: Validation of the Genomic Orientation Scale (GO Scale)

    Jul 1, 2021, 00:00

  • Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis

    Jul 1, 2021, 00:00

  • Copyright/Subscription

    Jul 1, 2021, 00:00

  • Table of Contents

    Jul 1, 2021, 00:00

  • Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies [Editor's Choice]

    Jul 1, 2021, 00:00

  • Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare [Editor's Choice]

    Jul 1, 2021, 00:00

  • Cost-Effectiveness Analyses of an Absorbable Antibacterial Envelope for Use in Patients at Increased Risk of Cardiac Implantable Electronic Device Infection in Germany, Italy, and England

    Jul 1, 2021, 00:00

  • Measuring Patient Preferences at the FDA Center for Devices and Radiological Health: Reflections and Projections

    Jul 1, 2021, 00:00

  • Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia

    Jul 1, 2021, 00:00

  • “Looking Under the Hood” of Anchor-Based Assessment of Clinically Important Change: A Machine Learning Approach [Editor's Choice]

    Jul 1, 2021, 00:00

  • Editorial Board

    Jun 9, 2021, 10:32

  • Individual's Health - Epidemiology Public Health

    Jun 1, 2021, 00:00

  • PCN159 Prediction of Low-VALUE Cancer Care Among Older Men with Low-Risk Prostate Cancer: A Machine Learning Approach

    Jun 1, 2021, 00:00

  • Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a “Shared Savings” Approach to Cost Offsets [Editor's Choice]

    Jun 1, 2021, 00:00

  • PCN6 Effects of Metformin Use on Progression-Free and Overall Survival of Glioblastoma Cancer Patients: A Systematic Review and Meta-Analysis

    Jun 1, 2021, 00:00

  • PCN216 Association of Patient Activation with the Health-Related Quality of Life of Patients with Pancreatic Cancer (PwPC)

    Jun 1, 2021, 00:00

  • PCV26 ALL-Cause and Bleeding Costs of Patients Initiating P2Y12 Inhibitors, Fxa Inhibitors, and Dabigatran

    Jun 1, 2021, 00:00

  • IN4 Non-Health Considerations in Economic Evaluations of COVID-19 Interventions: A Systemic Review

    Jun 1, 2021, 00:00

  • PCN62 Real-World Costs of FRONT-LINE Treatment for Peripheral T-Cell Lymphoma in France, Germany, and the United Kingdom

    Jun 1, 2021, 00:00

  • Medical Devices - Economic Evaluation

    Jun 1, 2021, 00:00

  • PRO76 Resource Utilization and Costs Among Patients with Glycogen Storage Disease Type Ia (GSDIa)

    Jun 1, 2021, 00:00

  • PCN82 Cost-Effectiveness of Once Weekly Selinexor-Bortezomib-Dexamethasone (XVD) in Previously Treated Multiple Myeloma (MM)

    Jun 1, 2021, 00:00

  • PIN30 Comparing Two Rotavirus Vaccines Strategies Versus NO Vaccine in China- a Cost-Effectiveness Analysis

    Jun 1, 2021, 00:00

  • PNS67 Gaining Trust in the Use of Virtual Meetings for Health Technology Assessment during the COVID-19 Pandemic

    Jun 1, 2021, 00:00

  • No Specific Disease - Conceptual Papers (CP)

    Jun 1, 2021, 00:00

  • PCN15 Increasing Disease Complexity Poses Challenges for Indirect Treatment Comparisons: An Example in Relapsed and Refractory Multiple Myeloma (RRMM)

    Jun 1, 2021, 00:00

  • PND3 Improvements in Migraine-specific Quality of Life Questionnaire (MSQ) Domain Scores with Fremanezumab and Galcanezumab in Patients with Multiple Prior Migraine Preventive Treatment Failures: A Network Meta-analysis

    Jun 1, 2021, 00:00

  • Economic Evaluation Applications: Burden and Value of Therapies

    Jun 1, 2021, 00:00

  • PMS33 Long- and Short-Term Disability and Workers' Compensation Trends for Employees with Systemic Lupus Erythematosus or Connective Tissue Disorders in the United States

    Jun 1, 2021, 00:00

  • RW3 Quantitative Bias Analysis (QBA) for Comparative Effectiveness of Alectinib versus Ceritinib in Non-Small Cell Lung Cancer (NSCLC)

    Jun 1, 2021, 00:00

  • PMU9 Budget Impact Analysis of Expanding Use of Recombinant Human Hyaluronidase-facilitated Subcutaneous Ig Infusion in patients with Primary Immunodeficiencies (PID) in Brazil

    Jun 1, 2021, 00:00

  • PNS4 The Consequences of Greater Net Price Transparency for Innovative Medicines: Insights from European Experts and Payers

    Jun 1, 2021, 00:00

  • PRO12 Early Pricing and Access Forecasting for Orphan Assets - Leveraging a Value-Driven Approach to Price Forecasting

    Jun 1, 2021, 00:00

  • Comparative Effectiveness Studies

    Jun 1, 2021, 00:00

  • PSU2 IMPACT of Recognized and Unrecognized Iatrogenic Lower Ureteral Injury at Time of Hysterectomy: A Nationwide Populational Database Study

    Jun 1, 2021, 00:00

  • PGI7 Correlation between Clinical Outcomes and HTA Decisions in Ulcerative Colitis

    Jun 1, 2021, 00:00

  • PNS56 Survey of the Awareness of Pharmacists about Quarantine Measures during the COVID-19 Pandemic

    Jun 1, 2021, 00:00

  • PSU3 The Impact of Operative Approach on Postoperative Outcomes and Health Care Utilization Following Colectomy

    Jun 1, 2021, 00:00

  • PCN215 Attributes Influencing Choice of Adjuvant Treatment for Muscle-Invasive Urothelial Cancer: Qualitative Research

    Jun 1, 2021, 00:00

  • PCN27 Real-World Characteristics and Outcomes of Patients with Metastatic Ductal Adenocarcinoma (MPDAC) Treated with Liposomal Irinotecan-Based Regimens By Race

    Jun 1, 2021, 00:00

  • Infectious Diseases - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PMH9 Economic Burden of Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the United States

    Jun 1, 2021, 00:00

  • Respiratory-Related Disorders - Organizational Practices

    Jun 1, 2021, 00:00

  • PCN124 Potential for Earlier Cancer Diagnosis to Reduce Cancer Deaths:Differences By Sex and Race/Ethnicity

    Jun 1, 2021, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PDG40 Assessing the Tuscany Region Response to COVID-19 Lockdown in NON-Hospital Supply of Antidiabetic Drugs: An Interrupted Time Series Analysis

    Jun 1, 2021, 00:00

  • PCN77 Cost-effectiveness analysis of adjuvant FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for resected pancreatic cancer in the United States: based on PRODIGE and APACT trial

    Jun 1, 2021, 00:00

  • No Specific Disease - Health Technology Assessment

    Jun 1, 2021, 00:00

  • PCV17 Cost Analysis of Myocardial Infarction and Ischemic Stroke Using the National Claims Database in Taiwan

    Jun 1, 2021, 00:00

  • PCN126 Treatment Pattern and Cost Estimation of Melanoma in Brazilian Public Healthcare System

    Jun 1, 2021, 00:00

  • PCN81 Economic Evaluation of First-LINE Atezolizumab for Extensive-STAGE SMALL-Cell LUNG Cancer: The Difference between the Standard Parametric MODEL and the Mixture Cure MODEL

    Jun 1, 2021, 00:00

  • Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios

    Jun 1, 2021, 00:00

  • PCN102 A Cost Comparison Study to Review Community Versus ACUTE Hospital Models of Nursing Care Delivered to Oncology Patients.

    Jun 1, 2021, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PCN23 The Development and Validation of a Simulation Model-based Clinical Decision Tool to Support Oncology Practice

    Jun 1, 2021, 00:00

  • PUK9 Economic Evaluation of Prostate-Specific Antigen Screening for Prostate Cancer in China

    Jun 1, 2021, 00:00

  • PCV39 Association between Social Determinants of Health, Heathcare Resource Utilization, Medication Adherence, and Medication Persistence Among Patients with Hypertension

    Jun 1, 2021, 00:00

  • PMH20 Antimuscarinic Prescribing Cascade with Acetylcholinesterase Inhibitor Use Among a National Cohort of Older Adults with Alzheimer's Disease

    Jun 1, 2021, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Medical Technologies

    Jun 1, 2021, 00:00

  • PDG41 Evaluating the Effectiveness and Safety and Economy of Domestic and Original Tigecycline for Injection in Real-World Based on PSM Method

    Jun 1, 2021, 00:00

  • PMU11 Economic Evaluation of Avatrombopag for Elective Diagnostic Procedure or Surgery of Thrombocytopenia in Adult Patients with Chronic LIVER Disease (CLD) in China

    Jun 1, 2021, 00:00

  • PPM6 Evaluating an Artificial Intelligence Powered Medication Adherence Program's Targeting by Patients' Socially Vulnerability

    Jun 1, 2021, 00:00

  • Predicting Potential Prevention Effects on Hospital Burden of Nosocomial Infections: A Multistate Modeling Approach

    Jun 1, 2021, 00:00

  • PIH15 Antimuscarinic Cascade across Individual Cholinesterase Inhibitors in Older Adults with Dementia

    Jun 1, 2021, 00:00

  • PSY6 Differences in All-Cause Health Care Costs of Alopecia Areata in the United States by Patient Subgroups: A Latent Class Approach

    Jun 1, 2021, 00:00

  • Economic Evaluation in Oncology Studies

    Jun 1, 2021, 00:00

  • PRO16 Clinical and Economic Consequences of the Breakthrough Hemolysis

    Jun 1, 2021, 00:00

  • PCN194 Comparing Complex Machine Learning Models to Predict Likelihood of Ovarian Cancer Using Medicare Claims DATA

    Jun 1, 2021, 00:00

  • PCN58 Estimation of Post-Infusion Costs of Care for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial

    Jun 1, 2021, 00:00

  • Drugs Process of Care

    Jun 1, 2021, 00:00

  • Cardiovascular Disorders - Medical Technologies

    Jun 1, 2021, 00:00

  • PIN5 Immunogenicity and Safety of the COVID-19 Vaccines Compared to Controls in Healthy Adults: A Systematic Review

    Jun 1, 2021, 00:00

  • PMU67 Comparison of Health-Related Quality of Life of Diabetic Adults with and without Cardiovascular Disease in the United States

    Jun 1, 2021, 00:00

  • PRO26 Cost of illness of Sickle Cell Disease in the US, Payer's Perspective: (CRESCENT).

    Jun 1, 2021, 00:00

  • Drugs Statistical Research

    Jun 1, 2021, 00:00

  • EC4 Real-World Healthcare Costs in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

    Jun 1, 2021, 00:00

  • PND5 Relationship between the Short-Form 12 (SF-12) and Schizophrenia Symptom Rating Scales in a Randomized Controlled Clinical Trial of Paliperidone Palmitate 3 Monthly Formulation

    Jun 1, 2021, 00:00

  • Expedited Partner Therapy for Sexually Transmitted Infections in Minnesota: A Mixed-Methods Review of Current Practices and Barriers to Implementation

    Jun 1, 2021, 00:00

  • PDB27 An Evaluation of the Use of Psychotropic Agents Among Adults 65 Years or Older with Type 2 Diabetes

    Jun 1, 2021, 00:00

  • Musculoskeletal Disorders - Clinical Outcomes

    Jun 1, 2021, 00:00

  • PCN135 Two-Week-Wait Referral and Mortality of Uterus Cancer

    Jun 1, 2021, 00:00

  • PCN224 Incorporating a Patient-Reported Symptom Burden Tool in Cancer Care Settings

    Jun 1, 2021, 00:00

  • PCN67 Estimating Cost-Effectiveness of Pembrolizumab in Advanced Esophageal Cancer Based on the Keynote-181 Trial

    Jun 1, 2021, 00:00

  • Individual's Health - Patient-Centered Research

    Jun 1, 2021, 00:00

  • Infectious Diseases - Health Policy Regulatory

    Jun 1, 2021, 00:00

  • PCV15 Cost-Effectiveness of Screening for and Treating Masked Hypertension with out-of-Office Blood Pressure Monitoring

    Jun 1, 2021, 00:00

  • PIN74 Health-Related Quality of Life (HRQoL) in COVID-19 Patients - a Systematic Literature Review

    Jun 1, 2021, 00:00

  • PCN61 Targeted Literature Review (TLR) of the Economic Burden and Cost-Effectiveness of Treatments for Advanced/Metastatic Melanoma

    Jun 1, 2021, 00:00

  • PCN200 Automating the Identification of Lines of Therapy from Real-World Data in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

    Jun 1, 2021, 00:00

  • PDB45 Continuous Glucose Monitoring (CGM) Trends Among US Adults with Type I Diabetes in National Health and Wellness Survey (NHWS)

    Jun 1, 2021, 00:00

  • PND2 Efficacy and Safety of Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review

    Jun 1, 2021, 00:00

  • PUK19 DATA Quality Considerations for Determining the IMPACT of the COVID-19 Pandemic on Outpatient Visits and Procedures in the United States

    Jun 1, 2021, 00:00

  • PND33 A Cost-Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting

    Jun 1, 2021, 00:00

  • PNS70 Societal Cost Savings Are Often Not Considered in NICE Decision Making

    Jun 1, 2021, 00:00

  • PSS8 The Economic Burden of Macular Edema (ME) Associated with Non-infectious Uveitis (NIU) – A US Commercial Payer’s Perspective

    Jun 1, 2021, 00:00

  • PGI8 An Exploratory Analysis of the Survival Benefits in Commercially Insured Patients with Hepatic Encephalopathy (HE) Treated with Rifaximin versus Lactulose Alone using US Claims Data

    Jun 1, 2021, 00:00

  • Systemic Disorders/Conditions - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • PCN222 Health Related Quality of Life (HRQoL) Review in Patients with Ovarian Cancer: A Systematic Literature Review (SLR)

    Jun 1, 2021, 00:00

  • Urinary/Kidney Disorders - Real World Data Information Systems

    Jun 1, 2021, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Health Technology Assessment

    Jun 1, 2021, 00:00

  • PCN201 Anonymous Online Cannabis Survey Captures Representative National Sample of People with Breast Cancer

    Jun 1, 2021, 00:00

  • PIN55 Strategies, Ministers of Health and New Regulations: Did We Win or Were We Won By the COVID-19 Pandemic in Brazil?

    Jun 1, 2021, 00:00

  • Musculoskeletal Disorders - Economic Evaluation

    Jun 1, 2021, 00:00

  • PDG19 Prescription Opioid Use in Women during Pregnancy - A Retrospective Analysis Using Texas Medicaid Prescription Claims Data

    Jun 1, 2021, 00:00

  • PMS29 Qualitative Study to Understand the Patient Experience of Knee Osteoarthritis (OA) and Assess the Content Validity of the Knee Injury and Osteoarthritis Outcome Score (KOOS) and HIP Disability and Osteoarthritis Outcome Score (HOOS) M ...

    Jun 1, 2021, 00:00

  • Systemic Disorders/Conditions - Health Service Delivery Process of Care

    Jun 1, 2021, 00:00

  • PDG5 Changes in Canadian Guidelines for Conducting Budget IMPACT Analysis

    Jun 1, 2021, 00:00

  • RE2 Modeling the Impact of Drug Pricing Policies on Innovation

    Jun 1, 2021, 00:00

  • PRO4 Uncertainty in Clinical Outcomes in the Treatment of Paediatric Orphan Indications with Licensed Therapies

    Jun 1, 2021, 00:00

  • PNS66 Stated Importance Versus Actual Impact: An Evaluation of HTA Practices to Incorporate Patient Perspectives in Value Assessments

    Jun 1, 2021, 00:00

  • PRO36 Prevalence of Friedreich Ataxia: A Systematic Literature Review

    Jun 1, 2021, 00:00

  • PCN83 Healthcare Resource Utilization (HCRU) of Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer (EC/GEJC) Receiving Adjuvant Nivolumab Treatment Versus Placebo:

    Jun 1, 2021, 00:00

  • PMU36 Effects of the Medicare PART D Comprehensive Medication Review on Medication Adherence Among Beneficiaries with Alzheimer's Disease

    Jun 1, 2021, 00:00

  • PGI24 Complications and Healthcare Utilization in Adult Patients Receiving Parenteral Support for Intestinal Failure Associated with Short Bowel Syndrome

    Jun 1, 2021, 00:00

  • PCN220 Conceptual Framework of Symptoms and Impacts Experienced By Patients with Nut Carcinoma

    Jun 1, 2021, 00:00

  • PDB12 Hospital Burden of Chronic Gout with and without Tophus Insured By Medicaid: A Propensity Score Matched Analysis of in-Patient Claims Database

    Jun 1, 2021, 00:00

  • PRO23 An Observational Cohort Analysis on the Economic IMPACT of Chronic Kidney Disease in Patients with Fabry Disease

    Jun 1, 2021, 00:00

  • PMS12 Healthcare Costs and Insurance Coverage of Rheumatoid Arthritis Patients in the United States: A 2018 Medical Expenditure Panel Survey Data Analysis

    Jun 1, 2021, 00:00

  • PCN94 Budget IMPACT of Changing Nivolumabe Doses: A Simulation in Health Insurance System

    Jun 1, 2021, 00:00

  • PSS11 Comparing Patient's Compliance and Persistence on Prostaglandin Analogs Using Real-World Utilization Databases for the Treatment of OPEN-Angle Glaucoma or Ocular Hypertension.

    Jun 1, 2021, 00:00

  • PCN174 Innovative Approaches to Cancer Therapy Provision in the COVID-Era

    Jun 1, 2021, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Patient-Centered Research

    Jun 1, 2021, 00:00

  • PDB43 eHealth Use Among Type 2 Diabetics: PRE-COVID Associations with Patient Activation, Preventive Behaviors, and Health Outcomes

    Jun 1, 2021, 00:00

  • PIH40 Screen-Based Media Use among Children and Adolescents: An Application of Unsupervised Topic Modeling

    Jun 1, 2021, 00:00

  • PND29 Scenario Analyses on Major Impactful and Uncertain Inputs of the Cost-Effectiveness Model of Fremanezumab From a Healthcare System Perspective in England

    Jun 1, 2021, 00:00

  • PMU27 Association of Osteoarthritis to Incident Cancer among Adults in the United States

    Jun 1, 2021, 00:00

  • PNS42 The Financial Burden of Medicine out of Pocket Payment Among Households in Ethiopia: An Analysis of Trends and Determinants

    Jun 1, 2021, 00:00

  • PRO61 Health-Related Quality of Life (HRQOL) and Healthcare Resource Use (HCRU) Associated with the Treatment of Pompe Disease (PD): Targeted Literature Reviews

    Jun 1, 2021, 00:00

  • PMH49 Factors Affecting Medication Nonadherence Among Patients with Psychiatric Illness in Tertiary Care Teaching Hospital in South India

    Jun 1, 2021, 00:00

  • PIH19 Dosing and Safety of Medical Cannabis in Children: Preliminary Findings from a Living Systematic Review

    Jun 1, 2021, 00:00

  • PCN236 A Retrospective Real-World Evidence Study of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) in the US Using the Optum Database

    Jun 1, 2021, 00:00

  • PCN151 The Geographical Association with LUNG Cancer Incidents, Mortality, and Accessibility of LUNG Cancer Screening in RURAL Appalachia

    Jun 1, 2021, 00:00

  • PCN19 Beyond a Binary Endpoint: Longitudinal and Individual Symptom Analyses from the Simplify-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor Naive Myelofibrosis Patients

    Jun 1, 2021, 00:00

  • PNS59 Current Utilization and Perceptions of Value Assessment Frameworks Among United States Payers

    Jun 1, 2021, 00:00

  • Cardiovascular Disorders - Clinical Outcomes

    Jun 1, 2021, 00:00

  • PCN71 Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Who Have Received Two or More Prior Lines of Therapies

    Jun 1, 2021, 00:00

  • PCN245 Examining Longitudinal Practice Patterns in the use of ANTI-PD-1 and ANTI-PD-L1 Inhibitors as First-Line Therapy in Non-Small Cell Lung Cancer Patients in the US

    Jun 1, 2021, 00:00

  • PRO27 Budget IMPACT Analysis of Pegvisomant in the Treatment Acromegaly in Colombia

    Jun 1, 2021, 00:00

  • CN4 Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab Versus Chlorambucil PLUS Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (ELEVATE-TN)

    Jun 1, 2021, 00:00

  • PMU38 Market Access Trends of Pharmaceutical Products in the EU5 and US (2009-2019)

    Jun 1, 2021, 00:00

  • Infectious Diseases - Conceptual Papers (CP)

    Jun 1, 2021, 00:00

  • PCN134 Assessing the Relationship between Immature and Mature Overall Survival (OS) Outcomes on HTA Decision-Making: A Study of UK Nice Decisions and the Case for Coverage with Evidence Development

    Jun 1, 2021, 00:00

  • Infectious Diseases - Clinical Outcomes

    Jun 1, 2021, 00:00

  • PNS17 Value of a Comprehensive Ophthalmology Custom Pack in a Canadian Setting

    Jun 1, 2021, 00:00

  • No Specific Disease - Economic Evaluation

    Jun 1, 2021, 00:00

  • PDB40 Eliciting Patient Preferences for Continuous Glucose Monitoring Devices in Type 1 Diabetes

    Jun 1, 2021, 00:00

  • Alternative Medicine Public Health

    Jun 1, 2021, 00:00

  • Medical Technology Studies

    Jun 1, 2021, 00:00
  • «
  • 31
  • 32
  • 33
  • 34 (current)
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • »